<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29211220</article-id><article-id pub-id-type="pmc">5701093</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Blood Transfusion and Increased Perioperative Risk in Coronary Artery
Bypass Grafts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Campos</surname><given-names>Igor C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tanganelli</surname><given-names>Valessa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maues</surname><given-names>Hugo P.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Coelho</surname><given-names>Marcio C. M.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Fernanda A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Munhoz</surname><given-names>Giovana</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Egito</surname><given-names>Julyana G. T.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Hayala C. C.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Giannini</surname><given-names>C&#x000e1;ssio M. C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Farsky</surname><given-names>Pedro S.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1">
<label>1</label> Instituto Dante Pazzanese de Cardiologia, S&#x000e3;o Paulo, SP,
Brazil.</aff><aff id="aff2">
<label>2</label> Laboratory of Statistics and Epidemiology, Instituto Dante
Pazzanese de Cardiologia, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff3">
<label>3</label> Funda&#x000e7;&#x000e3;o Pr&#x000f3;-Sangue, Instituto Dante Pazzanese
de Cardiologia, S&#x000e3;o Paulo, SP, Brazil.</aff><aff id="aff4">
<label>4</label> Instituto Dante Pazzanese de Cardiologia; Universidade de Santo
Amaro (UNISA), S&#x000e3;o Paulo, SP, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: Pedro Silvio Farsky, Rua Alberto Faria, 248
- Alto de Pinheiros - S&#x000e3;o Paulo, SP, Brazil - Zip code: 05459-000.
E-mail: <email>pedro.farsky@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2017</year></pub-date><volume>32</volume><issue>5</issue><fpage>394</fpage><lpage>400</lpage><history><date date-type="received"><day>21</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To correlate blood transfusions and clinical outcomes during hospitalization
in coronary artery bypass grafting surgery (CABG).</p></sec><sec><title>Methods</title><p>Transfusion, clinical and hematological data were collected for 1,378
patients undergoing isolated or combined CABG between January 2011 and
December 2012. The effect of blood transfusions was evaluated through
multivariate analysis to predict three co-primary outcomes: composite
ischemic events, composite infectious complications and hospital mortality.
Because higher risk patients receive more transfusions, the hospital
mortality outcome was also tested on a stratum of low-risk patients to
isolate the effect of preoperative risk on the results.</p></sec><sec><title>Results</title><p>The transfusion rate was 63.9%. The use of blood products was associated with
a higher incidence of the three coprimary outcomes: composite infectious
complications (OR 2.67, 95% CI 1.70 to 4.19; <italic>P</italic>&#x0003c;0.001),
composite ischemic events (OR 2.42, 95% CI 1.70 to 3.46;
<italic>P</italic>&#x0003c;0.001) and hospital mortality (OR 3.07, 95% CI 1.53 to
6.13; <italic>P</italic>&#x0003c;0.001). When only patients with logistic
EuroSCORE &#x02264; 2% were evaluated, <italic>i.e.</italic>, low-risk
individuals, the mortality rate and the incidence of ischemic events and
infectious complications composites remained higher among the transfused
patients [6% <italic>vs.</italic> 0.4% (<italic>P</italic>&#x0003c;0.001), 11.7%
<italic>vs.</italic> 24,3% (<italic>P</italic>&#x0003c;0.001) and 6.5%
<italic>vs.</italic> 12.7% (<italic>P</italic>=0.002),
respectively].</p></sec><sec><title>Conclusion</title><p>The use of blood components in patients undergoing CABG was associated with
ischemic events, infectious complications and hospital mortality, even in
low-risk patients.</p></sec></abstract><kwd-group><kwd>Blood transfusion</kwd><kwd>Bloodless Medical and Surgical Procedures</kwd><kwd>Myocardial Revascularization</kwd><kwd>Coronary Artery Bypass</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting surgery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1"> = Odds ratio</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>The use of blood products in cardiac surgery is a known risk factor for adverse
events during the perioperative period. Unnecessary transfusions can cause further
increases in surgical risk and complications. Blood transfusion criteria in this
scenario are not yet well established and exhibit variability between different
centers and among professionals at the same center.</p><p>Several studies, mostly observational, have demonstrated an association between pre-
and intraoperative anemia and increased morbidity and mortality after cardiac
surgery<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. A drop in hematocrit in the absence of shock has
been the main indication for transfusion in critically ill patients, and in up to
29% of these cases there is no clear justification for transfusion<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>A potential indication of transfusion is the association between severe anemia and
hypoxemia, which may increase postoperative risk, but this theory is not
confirmed.</p><p>Patients receiving transfusions are usually at a greater preoperative risk, added
with the risk of the event leading to transfusion. Preliminary studies show higher
mortality rates, ischemic and infectious outcomes, however, these previous studies
are not corrected for the individual risk of patients. Furthermore, these studies
evaluated patients submitted to general surgery, and when evaluated patients
undergoing cardiac surgery, are not specifically for coronary artery bypass surgery
(CABG)<sup>[<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>This study evaluates the association between blood transfusions and hospital
morbidity and mortality in patients undergoing CABG (isolated or combined);
furthermore, is analyzed a subgroup of low-risk patients, in order to minimize the
effects of the greater preoperative risk of the transfused patients, identified by a
low Logistic EuroSCORE.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Consecutive patients undergoing isolated or combined CABG between January
1<sup>st</sup> 2011 and December 31<sup>st</sup> 2012 were included in the
study. Patients aged &#x02264; 18 years or those who were not undergoing surgery with
a cardiopulmonary bypass were not selected.</p><p>The lowest hemoglobin values measured between a patient's departure from the
operating room until 10 days after surgery were included. Intraoperative hemoglobin
data were not included.</p><p>The transfusion of blood products (packed red cells, packed platelets, fresh frozen
plasma and cryoprecipitate), conducted between 5 days before and 10 days after CABG,
was considered to be of primary interest.</p><p>Blood transfusions were performed when hemoglobin levels fell below 7 g/dL or in
critical clinical conditions, at the physician's discretion.</p><p>Three co-primary outcomes were pre-specified: infectious outcomes, ischemic outcomes,
and hospital death.</p><p>An infectious outcome was defined as a composite of respiratory infection, wound
infection and/or sepsis. An ischemic outcome was defined as a composite of stroke,
transient ischemic attack, acute myocardial infarction and/or acute renal failure
(an increase in the creatinine value of at least 50% as per the Acute Renal Injury
Network<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>). Hospital
mortality was defined as death that occurred within 30 days of surgery or during
hospitalization<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>Demographic characteristics and comorbidities were obtained from institutional
databases, and data were organized by absolute and relative frequencies (qualitative
variables) and by mean and standard deviation (quantitative variables).</p><p>Information infrequently missing from the database (&#x0003c; 1%) was redistributed in the
median or most frequent category. Information more frequently missing (&#x0003e; 1%) was
considered void and was not included in analyses. The study was approved by the
Ethics Committee of each institution involved.</p><sec><title>Statistical Analysis</title><p>To compare quantitative variables from transfused and non-transfused patients,
Student's-t and Mann-Whitney tests were used according to the distribution of
variables. To compare groups by categorical variables, Fisher's exact test was
used.</p><p>Univariate analysis was performed between the transfusion and non-transfusion
groups using preoperative variables. These variables were included, with data on
the transfusion of blood products, in a multivariate logistic regression model
to predict mortality, infectious outcomes and ischemic outcomes. The odds ratio
(OR) and 95% confidence interval (CI) values were reported.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 1,389 patients underwent CABG during the study period. Eleven patients had
no transfusion data and were excluded. Clinical characteristics are described in
<xref ref-type="table" rid="t1">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Population characteristics (n=1,378).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Non-transfused (n=498)</th><th align="center" rowspan="1" colspan="1">Transfused (n=880)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 65 years</td><td align="center" rowspan="1" colspan="1">336 (67.5)</td><td align="center" rowspan="1" colspan="1">441 (50.1)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;65 to 75 years</td><td align="center" rowspan="1" colspan="1">136 (27.3)</td><td align="center" rowspan="1" colspan="1">308 (35)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265; 75 years</td><td align="center" rowspan="1" colspan="1">26 (5.2)</td><td align="center" rowspan="1" colspan="1">131 (14.9)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, n (%)</td><td align="center" rowspan="1" colspan="1">77 (15.5)</td><td align="center" rowspan="1" colspan="1">354 (40.2)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative Hb, g/dL</td><td align="center" rowspan="1" colspan="1">14.4&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">13.6&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Minimum Hb, g/dL</td><td align="center" rowspan="1" colspan="1">8.9&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">7.9&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="center" rowspan="1" colspan="1">80.6&#x000b1;14.1</td><td align="center" rowspan="1" colspan="1">72.8&#x000b1;14.1</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Anoxia time, minutes</td><td align="center" rowspan="1" colspan="1">50.6&#x000b1;20.6</td><td align="center" rowspan="1" colspan="1">61.7&#x000b1;25.1</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ECC time, minutes</td><td align="center" rowspan="1" colspan="1">74&#x000b1;29</td><td align="center" rowspan="1" colspan="1">93&#x000b1;38</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistical EuroSCORE (%)</td><td align="center" rowspan="1" colspan="1">3.18&#x000b1;4.54</td><td align="center" rowspan="1" colspan="1">5.82&#x000b1;7.9</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CrCl &#x02264; 30 mg/dL, n (%)</td><td align="center" rowspan="1" colspan="1">5 (1.1)</td><td align="center" rowspan="1" colspan="1">29 (3.5)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">EF &#x0003c; 50%, n (%)</td><td align="center" rowspan="1" colspan="1">181 (36.8)</td><td align="center" rowspan="1" colspan="1">322 (37)</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">199 (40)</td><td align="center" rowspan="1" colspan="1">371 (42.2)</td><td align="center" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">SAH, n (%)</td><td align="center" rowspan="1" colspan="1">429 (86.1)</td><td align="center" rowspan="1" colspan="1">764 (86.8)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker, n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Non-smoker</td><td align="center" rowspan="1" colspan="1">212 (42.6)</td><td align="center" rowspan="1" colspan="1">418 (47.5)</td><td align="center" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Current smoker</td><td align="center" rowspan="1" colspan="1">111 (22.3)</td><td align="center" rowspan="1" colspan="1">160 (18.2)</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ex-smoker (&#x0003e; 1 year)</td><td align="center" rowspan="1" colspan="1">175 (35.1)</td><td align="center" rowspan="1" colspan="1">302 (34.3)</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;COPD, n (%)</td><td align="center" rowspan="1" colspan="1">22 (4.4)</td><td align="center" rowspan="1" colspan="1">43 (4.9)</td><td align="center" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior stroke/TIA, n (%)</td><td align="center" rowspan="1" colspan="1">25 (5)</td><td align="center" rowspan="1" colspan="1">54 (6.1)</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Carotid disease (&#x0003e; 50%), n (%)</td><td align="center" rowspan="1" colspan="1">20 (4)</td><td align="center" rowspan="1" colspan="1">54 (6.1)</td><td align="center" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peripheral vascular disease, n (%)</td><td align="center" rowspan="1" colspan="1">38 (7.6)</td><td align="center" rowspan="1" colspan="1">82 (9.3)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AMI in last 30 days, n (%)</td><td align="center" rowspan="1" colspan="1">64 (12.9)</td><td align="center" rowspan="1" colspan="1">144 (16.4)</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Combined MR, n (%)</td><td align="center" rowspan="1" colspan="1">54 (10.8)</td><td align="center" rowspan="1" colspan="1">188 (21.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Affected arteries, n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Uni or biarterial</td><td align="center" rowspan="1" colspan="1">146 (30.3)</td><td align="center" rowspan="1" colspan="1">205 (24.4)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Triarterial or trunk</td><td align="center" rowspan="1" colspan="1">336 (69.7)</td><td align="center" rowspan="1" colspan="1">635 (75.6)</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AMI=acute myocardial infarction; COPD=chronic obstructive pulmonary
disease; CrCl=creatinine clearance; ECC=extracorporeal circulation;
EF=ejection fraction; Hb=hemoglobin; MR=myocardial revascularization
surgery; SAH=systemic arterial hypertension; TIA=transitory ischemic
attack</p></fn></table-wrap-foot></table-wrap><p>Among the 1,378 patients included, 498 (36.1%) did not receive any type of blood
product transfusion and 880 (63.9%) received one or more. Of these, 63 (4.6% of the
total) individuals received only blood components other than packed red blood cells,
and 817 (59.3%) received at least one packed red blood cell product, with or without
other blood products. The percentage of patients using each of the blood products
studied and the mean numbers of transfused bags are listed in <xref ref-type="table" rid="t2">Table 2</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Transfusion rates and mean transfused units.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">Mean units &#x000b1; SD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Packed red blood cells</td><td align="center" rowspan="1" colspan="1">817 (59.3)</td><td align="center" rowspan="1" colspan="1">2.37&#x000b1;1.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Packed platelets</td><td align="center" rowspan="1" colspan="1">157 (11.4)</td><td align="center" rowspan="1" colspan="1">8.34&#x000b1;6.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Cryoprecipitate</td><td align="center" rowspan="1" colspan="1">82 (6)</td><td align="center" rowspan="1" colspan="1">8.04&#x000b1;3.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Fresh frozen plasma</td><td align="center" rowspan="1" colspan="1">274 (19.9)</td><td align="center" rowspan="1" colspan="1">2.77&#x000b1;2.12</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>SD=standard deviation</p></fn></table-wrap-foot></table-wrap><p>The transfused patients were older, had lower body weight, preoperative hemoglobin
values and minimum hemoglobin values in the first 10 days after surgery, and had
higher logistical EuroSCOREs than control patients. Anoxia and cardiopulmonary
bypass times were significantly longer in this group. The proportion of women,
number of patients with stage 4 or 5 kidney failure, and incidence of combined
surgery and triarterial or trunk injuries were significantly higher among transfused
patients.</p><p>The incidence of composite infectious outcomes among transfusion patients was 16.1%
compared to 6% among the non-transfused (OR 3; 95% CI 1.99 to 4.53;
<italic>P</italic>&#x0003c;0.001]. This association was also significant when each of
its components was evaluated [sepsis 3% <italic>vs.</italic> 0.6% (OR 5.02, 95% CI
1.51 to 16.68; <italic>P</italic>&#x0003c;0.001), respiratory infection 8.6%
<italic>vs.</italic> 2.6% (OR 3.53, 95% CI 1.94 to 6.42;
<italic>P</italic>&#x0003c;0.001), surgical wound infection 9.7% <italic>vs.</italic>
3.6% (OR 2.77, 95% CI 1.59 to 4.80; <italic>P</italic> &#x0003c;0.001)].</p><p>Ischemic outcomes occurred in 29.4% of the transfused group and in 12.6% of the
non-transfused (OR 2.91, 95% CI 2.13 to 3.98; <italic>P</italic>&#x0003c;0.001). As with
infectious outcomes, there was also an association between transfusion and each
component of ischemic outcomes [kidney failure 21% <italic>vs.</italic> 9.3% (OR
2.58, 95% CI 1.81 to 3.68; <italic>P</italic>&#x0003c;0.001), stroke 4.1%
<italic>vs.</italic> 1.8% (OR 2.32, 95% CI 1.11 to 4.85;
<italic>P</italic>&#x0003c;0.001), acute perioperative myocardial infarction 8%
<italic>vs.</italic> 2.2% (OR 3.83, 95% CI 2.01 to 7.30;
<italic>P</italic>&#x0003c;0.001)].</p><p>Hospital mortality among transfused patients was significantly higher than among
non-transfused patients [10% <italic>vs.</italic> 2.2% (OR 4.92, 95% CI 2.6 to 9.3;
<italic>P</italic>&#x0003c;0.001)].</p><p>In the low-risk group, patients identified by logistic EuroSCORE &#x02264; 2% (252
transfused and 260 non-transfused patients), had a mortality of 6%
<italic>vs.</italic> 0.4% (<italic>P</italic>&#x0003c;0.001) for the transfused and
non-transfused group, ischemic outcome of 11.7% <italic>vs.</italic> 24.3%
(<italic>P</italic>&#x0003c;0.001) and infectious outcome 6.5% <italic>vs.</italic>
12.7% (<italic>P</italic>=0.002).</p><p>When adjusted by a multivariate logistic model, the association between transfusion
and the three co-primary outcomes was maintained in relation to composite infectious
outcomes (OR 2.67, 95% CI 1.70 to 4.19; <italic>P</italic>&#x0003c;0.001), composite
ischemic outcomes (OR 2.42, 95% CI 1.70 to 3.46; <italic>P</italic>&#x0003c;0.001) and
hospital mortality (OR 3.07, 95% CI 1.53 to 6.13; <italic>P</italic>&#x0003c;0.001)
(<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Outcomes in patients with EuroSCORE &#x02264; 2</p></caption><graphic xlink:href="rbccv-32-05-0394-g01"/></fig>
</p><p>In our study, other variables were identified as independent predictors of the three
outcomes, as follows: mortality (creatinine clearance &#x0003c; 30%, age &#x0003e; 75 years,
diabetes mellitus, family history of coronary artery disease and current smoking),
infectious outcomes (creatinine clearance &#x02264; 30%, age &#x02265; 75 years,
chronic obstructive pulmonary disease and high body mass index) and ischemic
outcomes (family history of coronary artery disease and female gender).</p><p>Among the 17 surgeons who performed CABG during the study period, excluding those who
performed fewer than 10 procedures (5 professionals), the transfusion rate ranged
from 53% to 79% (<italic>P</italic>&#x0003c;0.001).</p><p>
<xref ref-type="table" rid="t3">Table 3</xref> shows data from the multivariate
logistic analysis for the prediction of the three co-primary outcomes.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Multivariate logistic analysis for the prediction of three co-primary
outcomes.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="28%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Mortality</th><th align="center" colspan="2" rowspan="1">Infectious outcome</th><th align="center" colspan="2" rowspan="1">Ischemic outcome</th></tr><tr><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Transfusion</td><td align="center" rowspan="1" colspan="1">3.07 (1.53-6.13)</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">2.67 (1.7-4.19)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" rowspan="1" colspan="1">2.42 (1.7-3.46)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;65-75 years</td><td align="center" rowspan="1" colspan="1">1.38 (0.79-2.41)</td><td align="center" rowspan="1" colspan="1">0.257</td><td align="center" rowspan="1" colspan="1">1.36 (0.91-2.02)</td><td align="center" rowspan="1" colspan="1">0.136</td><td align="center" rowspan="1" colspan="1">1.22 (0.88-1.69)</td><td align="center" rowspan="1" colspan="1">0.231</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265; 75 years</td><td align="center" rowspan="1" colspan="1">3.37 (1.75-6.48)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" rowspan="1" colspan="1">2.24 (1.32-3.82)</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">1.43 (0.9-2.26)</td><td align="center" rowspan="1" colspan="1">0.126</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">1.07 (0.64-1.79)</td><td align="center" rowspan="1" colspan="1">0.795</td><td align="center" rowspan="1" colspan="1">1.36 (0.92-2.01)</td><td align="center" rowspan="1" colspan="1">0.119</td><td align="center" rowspan="1" colspan="1">1.47 (1.07-2.02)</td><td align="center" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">1.02 (0.97-1.07)</td><td align="center" rowspan="1" colspan="1">0.434</td><td align="center" rowspan="1" colspan="1">1.11 (1.07-1.15)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" rowspan="1" colspan="1">1.03 (0.99-1.06)</td><td align="center" rowspan="1" colspan="1">0.114</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative Hb, g/dL</td><td align="center" rowspan="1" colspan="1">0.91 (0.78-1.06)</td><td align="center" rowspan="1" colspan="1">0.223</td><td align="center" rowspan="1" colspan="1">1.06 (0.94-1.19)</td><td align="center" rowspan="1" colspan="1">0.319</td><td align="center" rowspan="1" colspan="1">0.96 (0.87-1.05)</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">CrCl &#x02264; 30 mg/dL</td><td align="center" rowspan="1" colspan="1">2.98 (1.11-8.02)</td><td align="center" rowspan="1" colspan="1">0.030</td><td align="center" rowspan="1" colspan="1">2.99 (1.24-7.23)</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">0.42 (0.15-1.16)</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">SAH</td><td align="center" rowspan="1" colspan="1">2.32 (0.89-6.08)</td><td align="center" rowspan="1" colspan="1">0.086</td><td align="center" rowspan="1" colspan="1">1.46 (0.77-2.79)</td><td align="center" rowspan="1" colspan="1">0.245</td><td align="center" rowspan="1" colspan="1">1.54 (0.96-2.49)</td><td align="center" rowspan="1" colspan="1">0.076</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">1.73 (1.08-2.78)</td><td align="center" rowspan="1" colspan="1">0.023</td><td align="center" rowspan="1" colspan="1">1.25 (0.88-1.78)</td><td align="center" rowspan="1" colspan="1">0.206</td><td align="center" rowspan="1" colspan="1">1.29 (0.97-1.72)</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Family history of CAD</td><td align="center" rowspan="1" colspan="1">2.36 (1.11-5)</td><td align="center" rowspan="1" colspan="1">0.025</td><td align="center" rowspan="1" colspan="1">0.91 (0.45-1.84)</td><td align="center" rowspan="1" colspan="1">0.797</td><td align="center" rowspan="1" colspan="1">1.81 (1.1-2.96)</td><td align="center" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">Tobacco use</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ex-smoker</td><td align="center" rowspan="1" colspan="1">1.17 (0.68-2.03)</td><td align="center" rowspan="1" colspan="1">0.566</td><td align="center" rowspan="1" colspan="1">0.99 (0.66-1.49)</td><td align="center" rowspan="1" colspan="1">0.975</td><td align="center" rowspan="1" colspan="1">0.85 (0.61-1.18)</td><td align="center" rowspan="1" colspan="1">0.328</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Current smoker</td><td align="center" rowspan="1" colspan="1">2 (1.05-3.78)</td><td align="center" rowspan="1" colspan="1">0.034</td><td align="center" rowspan="1" colspan="1">1.5 (0.93-2.42)</td><td align="center" rowspan="1" colspan="1">0.096</td><td align="center" rowspan="1" colspan="1">1.08 (0.72-1.61)</td><td align="center" rowspan="1" colspan="1">0.712</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;COPD</td><td align="center" rowspan="1" colspan="1">1.33 (051-3.5)</td><td align="center" rowspan="1" colspan="1">0.558</td><td align="center" rowspan="1" colspan="1">2.17 (1.08-4.37)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">1.49 (0.79-2.8)</td><td align="center" rowspan="1" colspan="1">0.221</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior stroke</td><td align="center" rowspan="1" colspan="1">1.72 (0.71-4.19)</td><td align="center" rowspan="1" colspan="1">0.229</td><td align="center" rowspan="1" colspan="1">1.27 (0.61-2.63)</td><td align="center" rowspan="1" colspan="1">0.527</td><td align="center" rowspan="1" colspan="1">1.34 (0.73-2.48)</td><td align="center" rowspan="1" colspan="1">0.345</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior TIA</td><td align="center" rowspan="1" colspan="1">1.14 (013-9.85)</td><td align="center" rowspan="1" colspan="1">0.906</td><td align="center" rowspan="1" colspan="1">0.53 (0.06-4.35)</td><td align="center" rowspan="1" colspan="1">0.555</td><td align="center" rowspan="1" colspan="1">0.29 (0.04-2.37)</td><td align="center" rowspan="1" colspan="1">0.247</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Carotid disease &#x02265; 50%</td><td align="center" rowspan="1" colspan="1">0.54 (0.19-1.51)</td><td align="center" rowspan="1" colspan="1">0.242</td><td align="center" rowspan="1" colspan="1">1.53 (0.79-2.94)</td><td align="center" rowspan="1" colspan="1">0.206</td><td align="center" rowspan="1" colspan="1">1.3 (0.72-2.34)</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peripheral vascular disease</td><td align="center" rowspan="1" colspan="1">1.8 (0.9-3.61)</td><td align="center" rowspan="1" colspan="1">0.096</td><td align="center" rowspan="1" colspan="1">1.35 (0.76-2.4)</td><td align="center" rowspan="1" colspan="1">0.302</td><td align="center" rowspan="1" colspan="1">1.29 (0.79-2.11)</td><td align="center" rowspan="1" colspan="1">0.311</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prior AMI</td><td align="center" rowspan="1" colspan="1">1.29 (0.79-2.11)</td><td align="center" rowspan="1" colspan="1">0.311</td><td align="center" rowspan="1" colspan="1">1.2 (0.84-1.72)</td><td align="center" rowspan="1" colspan="1">0.324</td><td align="center" rowspan="1" colspan="1">1.07 (0.8-1.44)</td><td align="center" rowspan="1" colspan="1">0.643</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Triarterial or trunk injury</td><td align="center" rowspan="1" colspan="1">1 (0.58-1.73)</td><td align="center" rowspan="1" colspan="1">0.996</td><td align="center" rowspan="1" colspan="1">1.26 (0.84-1.91)</td><td align="center" rowspan="1" colspan="1">0.267</td><td align="center" rowspan="1" colspan="1">1.21 (0.87-1.68)</td><td align="center" rowspan="1" colspan="1">0.267</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EF &#x0003c; 50%</td><td align="center" rowspan="1" colspan="1">0.98 (0.6-1.62)</td><td align="center" rowspan="1" colspan="1">0.949</td><td align="center" rowspan="1" colspan="1">0.91 (0.63-1.32)</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.87 (0.64-1.18)</td><td align="center" rowspan="1" colspan="1">0.354</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>AMI=acute myocardial infarction; BMI=body mass index; CAD=coronary artery
disease; CI 95%=95% confidence interval; COPD=chronic obstructive
pulmonary disease; CrCl=creatinine clearance; EF=ejection fraction;
Hb=hemoglobin; OR=odds ratio; SAH=systemic arterial hypertension;
TIA=transitory ischemic attack</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This retrospective study of 1,378 consecutive patients undergoing CABG revealed an
association between blood transfusion and composite infectious and ischemic outcomes
and mortality. Transfused patients are, as a group, at higher surgical risk;
however, when only low-risk patients were selected by EuroSCORE, mortality remained
high in the transfused group.</p><p>A blood product transfusion rate of 63.9% was found in this study. When only patients
receiving packed red blood cells, with or without other blood components, were
considered, the proportion was 59.3%. This value is consistent with the findings of
other studies<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. However, a downward trend in transfusion rates
and the number of transfused bags has been observed in recent years<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>We used a 7 g/dL as a threshold to transfusion, but, in case of critical clinical
events, the transfusion was indicated at higher levels of hemoglobin.</p><p>There was great variability in transfusion frequency among different surgeons,
although a significant portion of these transfusions was performed in the intensive
care unit.</p><p>As expected, transfused patients were a group of patients with higher risk of death
and comorbidities. However, even in the low-risk group, identified as a low
EuroSCORE risk (below 2%), there was an association between transfusion and
morbidity and mortality.</p><sec><title>Composite Infectious Outcomes</title><p>A composite infectious outcome, defined as sepsis, respiratory infection and
surgical wound infection, was significantly more prevalent among patients
undergoing blood transfusions (16.1% <italic>vs.</italic> 6%). This relationship
has been demonstrated in several publications<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> and is believed to be related to the socalled
"immunomodulating effect" of transfusion. This includes changes in blood cell
compositions, such as a decreased number of circulating lymphocytes, changes in
the T <italic>helper</italic>/T <italic>suppressor</italic> lymphocyte ratio and
immune cell activation<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.
These changes ultimately predispose the individual to susceptibility to
infectious agents, particularly bacteria. Perioperative blood transfusion
enhances the already established inflammatory status caused by cardiopulmonary
bypass and surgical trauma, increasing the levels of circulating cytokines by up
to 15 times<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>Some authors have suggested that the leukodepletion of blood products decreases
cytokine levels, reducing the deleterious effects of transfusion, but this has
not translated into improved clinical outcomes in subsequent studies<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Our study did not include
this analysis due to its low frequency in our cohort and because it is not a
common practice in Brazil.</p></sec><sec><title>Composite Ischemic Outcomes</title><p>Following the findings of previous studies that have shown an association between
transfusion and tissue ischemia in patients undergoing CABG, our results
demonstrated a higher incidence of composite kidney failure, stroke and acute
perioperative myocardial infarction among transfused patients (29.4%
<italic>vs.</italic> 12.6%). How blood transfusions lead to ischemic
complications in these patients is not fully understood, but it is believed that
the previously described inflammatory changes are responsible for these
findings. Additional molecular, biochemical and structural changes caused by the
storage of bags lead to decreased concentrations of 2 3-diphosphoglycerate,
fragility and lower red blood cell distensibility, reducing their capacity to
supply oxygen to tissues<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p></sec><sec><title>Mortality</title><p>The risk of death was three times higher among transfused patients when compared
to the non-transfused. The former significantly higher average EuroSCORE; older
age; a higher prevalence of combined surgeries, severe coronary lesions, and
kidney failure; and lower hemoglobin levels indicate that this is a group with
higher preoperative morbidity. This observation could raise questions about the
real effect of transfusion on outcomes. However, when adjusted for these and
other variables, transfusion remains an independent risk factor for mortality
and combined outcomes.</p><p>Other information contradicting the hypothesis that the higher mortality in the
transfused group stems from patients' conditions being more severe was provided
by an analysis of mortality in low-risk strata. When only patients with low
logistic EuroSCORE (&#x02264; 2%) were evaluated in both groups, the mortality
rate among the transfused remained significantly higher.</p></sec><sec><title>Low-Risk Group</title><p>The highest mortality rate, infection and ischemic outcomes in the transfusion
group may not be due to transfusion, but due to complications after CABG in a
high-risk group. This are important confounders in studies evaluating
transfusion after CABG. Patients receiving blood products are part of a higher
risk group, due to their high number of comorbidities. In addition, it is the
situation that caused the major bleeding, with its tissue hypoxia complications,
an additional surgical procedure to correct the bleeding and the possible
adverse effects of transfusion. Transfused patients more frequently require
inotropic and mechanical support. Despite careful statistical adjustments, it is
possible that these factors caused additional risk.</p><p>When patients with low baseline risk profiles were selected by logistic EuroSCORE
&#x0003c; 2%, confounding factors were reduced. In this scenario, significantly
higher mortality remained in the group receiving transfusions, as well as higher
ischemic and infectious outcomes, possibly due to tissue hypoxia complications,
could be a possibility caused by anemia/hypoperfusion associated with the
deleterious effects of transfusion.</p><p>A recent prospective, randomized study<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> testing the use of liberal or restrictive transfusion
strategies, defined by the use of a threshold for transfusion of 9.0 g/dL or 7.0
g/dL, did not show differences between the two subgroups. However, the
difference in hemoglobin levels between the groups was only 1 g/dL.</p><p>As expected, the minimum postoperative hemoglobin level in transfused individuals
was significantly lower than in patients who did not receive transfusions
(7.9&#x000b1;1.2 <italic>vs.</italic> 8.9&#x000b1;1.3). These values, rather than
a patient's actual clinical indication, guide transfusion indications in the
operating room, especially in surgery involving cardiopulmonary
bypass<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. The use of
a restrictive transfusion strategy has proven to be well tolerated by patients
in various studies. In a randomized clinical trial of patients undergoing CABG,
Bracey et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> reported
that a reduction in the transfusion hemoglobin threshold to 8 mg/dL did not
negatively affect outcomes and resulted in lower costs. In a large multicenter
study of critically ill patients not undergoing cardiac surgery, Hebert et
al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> found that a
restrictive strategy (hemoglobin &#x0003c; 7 mg/dL) could be superior to a liberal
strategy (hemoglobin &#x0003c; 10 mg/ dL). Results such as these lend support to the
global trend of the reduction of tolerated hemoglobin and hematocrit levels and
hence the performance of fewer transfusions on these patients.</p><p>Although guidelines for transfusion practices in cardiac surgery have already
been published<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, and
despite all the evidence made available during the last three decades of
research, there remains great variability in the performance of transfusions
among institutions and even among professionals in the same
institution<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Over
20 years ago, Goodnough et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> study demonstrated significant variability in transfusion
rates in 540 patients undergoing cardiac surgery in 18 institutions (17% to 100%
for packed red blood cells). In 2010, Bennett-Guerrero et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> found similar rates (7.8% to
92.8%) in a retrospective analysis of CABGs performed in 2008 across 798
centers. This demonstrates the lack of consensus on the level of hematocrit
required to ensure the benefits of transfusion over the potential risks. The
indication for transfusion derives, above all, from the personal judgment of
surgeons, anesthetists and clinicians, often to the detriment of an individual's
clinical condition. It is the professionals, rather than the patients
themselves, who do not tolerate low levels of hemoglobin and hematocrit.</p></sec><sec><title>Study Limitations</title><p>The main limitation of the study relates to the reasons, aside from hemoglobin
values, for blood transfusion. The reason for performing the transfusion, a
surgical complication resulting in bleeding, may itself be associated with high
morbidity and mortality, regardless of transfusion.</p><p>As this was a retrospective study, the results allowed us to evaluate the
association between the transfusion variable and morbidity and mortality
outcomes, but we cannot demonstrate causality among them. Another limitation,
also related to the retrospective nature of this study, is the lack of data
determining the period in which the transfusion and outcome occurred during
hospitalization. Furthermore, this study used mortality from all causes as a
primary outcome and did not differentiate between cardiac and non-cardiac causes
of death. There is no data concerning transfusion of critical clinical patients,
which are associated with higher incidence of complications.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In this study, the transfusion of blood products was found to be harmful for most
patients undergoing CABG, even in those with low baseline risk. Studies evaluating
whether the higher incidence of complications in these patients is due to blood
transfusion or to hypoxia complications are necessary to better understand
transfusion practice.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ICC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VT</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MCMC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FAM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JGTE</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HCCS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CMCG</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PSF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Instituto Dante Pazzanese de Cardiologia,
S&#x000e3;o Paulo, SP, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name><name><surname>Conti</surname><given-names>D</given-names></name><name><surname>Castelvecchio</surname><given-names>S</given-names></name><name><surname>Menicanti</surname><given-names>L</given-names></name><name><surname>Frigiola</surname><given-names>A</given-names></name><name><surname>Ballotta</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hematocrit on cardiopulmonary bypass and outcome after coronary
surgery in non-transfused patients</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>1</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">20103197</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zindrou</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>KM</given-names></name><name><surname>Bagger</surname><given-names>JP</given-names></name></person-group><article-title>Preoperative haemoglobin concentration and mortality rate after
coronary artery bypass surgery</article-title><source>Lancet</source><year>2002</year><volume>359</volume><issue>9319</issue><fpage>1747</fpage><lpage>1748</lpage><pub-id pub-id-type="pmid">12049866</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corwin</surname><given-names>HL</given-names></name><name><surname>Parsonnet</surname><given-names>KC</given-names></name><name><surname>Gettinger</surname><given-names>A</given-names></name></person-group><article-title>RBC transfusion in the ICU. Is there a reason?</article-title><source>Chest</source><year>1995</year><volume>108</volume><issue>3</issue><fpage>767</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">7656631</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>CG</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Duncan</surname><given-names>AI</given-names></name><name><surname>Mihaljevic</surname><given-names>T</given-names></name><name><surname>Loop</surname><given-names>FD</given-names></name><name><surname>Starr</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Transfusion in coronary artery bypass grafting is associated with
reduced long-term survival</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>81</volume><issue>5</issue><fpage>1650</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">16631651</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GJ</given-names></name><name><surname>Reeves</surname><given-names>BC</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Rizvi</surname><given-names>SI</given-names></name><name><surname>Culliford</surname><given-names>L</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name></person-group><article-title>Increased mortality, postoperative morbidity, and cost after red
blood cell transfusion in patients having cardiac surgery</article-title><source>Circulation</source><year>2007</year><volume>116</volume><issue>22</issue><fpage>2544</fpage><lpage>2552</lpage><pub-id pub-id-type="pmid">17998460</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paone</surname><given-names>G</given-names></name><name><surname>Likosky</surname><given-names>DS</given-names></name><name><surname>Brewer</surname><given-names>R</given-names></name><name><surname>Theurer</surname><given-names>PF</given-names></name><name><surname>Bell</surname><given-names>GF</given-names></name><name><surname>Cogan</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Transfusion of 1 and 2 units of red blood cells is associated
with increased morbidity and mortality</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>97</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">24094521</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Shah</surname><given-names>SV</given-names></name><name><surname>Molitoris</surname><given-names>BA</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Warnock</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Acute Kidney Injury Network: report of an initiative to improve
outcomes in acute kidney injury</article-title><source>Crit Care</source><year>2007</year><volume>11</volume><issue>2</issue><fpage>R31</fpage><lpage>R31</lpage><pub-id pub-id-type="pmid">17331245</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>P</given-names></name><name><surname>Berry</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>JNS</given-names></name></person-group><source>Statistical methods in medical research</source><edition>3rd ed.</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Blackwell Science</publisher-name><year>1994</year></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevde</surname><given-names>K</given-names></name><name><surname>Pagala</surname><given-names>M</given-names></name><name><surname>Kashikar</surname><given-names>A</given-names></name><name><surname>Tyagaraj</surname><given-names>C</given-names></name><name><surname>Shahbaz</surname><given-names>N</given-names></name><name><surname>Iqbal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gender is an essential determinant of blood transfusion in
patients undergoing coronary artery bypass graft procedure</article-title><source>J Clin Anesth</source><year>2000</year><volume>12</volume><issue>2</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">10818324</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett-Guerrero</surname><given-names>E</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><name><surname>TB</surname><given-names>Ferguson</given-names><suffix>Jr.</suffix></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Gammie</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Variation in use of blood transfusion in coronary artery bypass
graft surgery</article-title><source>JAMA</source><year>2010</year><volume>304</volume><issue>14</issue><fpage>1568</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">20940382</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremke</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Bak</surname><given-names>M</given-names></name><name><surname>Kristensen</surname><given-names>KL</given-names></name><name><surname>Hindsholm</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Antiplatelet therapy at the time of coronary artery bypass
grafting: a multicentre cohort study</article-title><source>Eur J Cardiothorac Surg</source><year>2013</year><volume>44</volume><issue>2</issue><fpage>e133</fpage><lpage>e140</lpage><pub-id pub-id-type="pmid">23660554</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despotis</surname><given-names>GJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lublin</surname><given-names>DM</given-names></name></person-group><article-title>Transfusion risks and transfusionrelated pro-inflammatory
responses</article-title><source>Hematol Oncol Clin North Am</source><year>2007</year><volume>21</volume><issue>1</issue><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">17258124</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>ET</given-names></name><name><surname>GL</surname><given-names>Wright</given-names><suffix>Jr.</suffix></name><name><surname>Dalmasso</surname><given-names>EA</given-names></name></person-group><article-title>Proteomic strategies for biomarker identification: progress and
challenges</article-title><source>Curr Opin Mol Ther</source><year>2000</year><volume>2</volume><issue>6</issue><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">11249741</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fransen</surname><given-names>E</given-names></name><name><surname>Maessen</surname><given-names>J</given-names></name><name><surname>Dentener</surname><given-names>M</given-names></name><name><surname>Senden</surname><given-names>N</given-names></name><name><surname>Buurman</surname><given-names>W</given-names></name></person-group><article-title>Impact of blood transfusions on inflammatory mediator release in
patients undergoing cardiac surgery</article-title><source>Chest</source><year>1999</year><volume>116</volume><issue>5</issue><fpage>1233</fpage><lpage>1239</lpage><pub-id pub-id-type="pmid">10559080</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hilten</surname><given-names>JA</given-names></name><name><surname>van de Watering</surname><given-names>LM</given-names></name><name><surname>van Bockel</surname><given-names>JH</given-names></name><name><surname>van de Velde</surname><given-names>CJ</given-names></name><name><surname>Kievit</surname><given-names>J</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of transfusion with red cells filtered to remove
leucocytes: randomised controlled trial in patients undergoing major
surgery</article-title><source>BMJ</source><year>2004</year><volume>328</volume><issue>7451</issue><fpage>1281</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">15142885</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuduvalli</surname><given-names>M</given-names></name><name><surname>Oo</surname><given-names>AY</given-names></name><name><surname>Newall</surname><given-names>N</given-names></name><name><surname>Grayson</surname><given-names>AD</given-names></name><name><surname>Jackson</surname><given-names>M</given-names></name><name><surname>Desmond</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Effect of peri-operative red blood cell transfusion on 30-day and
1-year mortality following coronary artery bypass surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>27</volume><issue>4</issue><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">15784356</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GJ</given-names></name><name><surname>Pike</surname><given-names>K</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Wordsworth</surname><given-names>S</given-names></name><name><surname>Stokes</surname><given-names>EA</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Liberal or restrictive transfusion after cardiac
surgery</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>11</issue><fpage>997</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">25760354</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engoren</surname><given-names>MC</given-names></name><name><surname>Habib</surname><given-names>RH</given-names></name><name><surname>Zacharias</surname><given-names>A</given-names></name><name><surname>Schwann</surname><given-names>TA</given-names></name><name><surname>Riordan</surname><given-names>CJ</given-names></name><name><surname>Durham</surname><given-names>SJ</given-names></name></person-group><article-title>Effect of blood transfusion on long-term survival after cardiac
operation</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>4</issue><fpage>1180</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">12400765</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracey</surname><given-names>AW</given-names></name><name><surname>Radovancevic</surname><given-names>R</given-names></name><name><surname>Riggs</surname><given-names>SA</given-names></name><name><surname>Houston</surname><given-names>S</given-names></name><name><surname>Cozart</surname><given-names>H</given-names></name><name><surname>Vaughn</surname><given-names>WK</given-names></name><etal/></person-group><article-title>Lowering the hemoglobin threshold for transfusion in coronary
artery bypass procedures: effect on patient outcome</article-title><source>Transfusion</source><year>1999</year><volume>39</volume><issue>10</issue><fpage>1070</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">10532600</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>PC</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Blajchman</surname><given-names>MA</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Pagliarello</surname><given-names>G</given-names></name><etal/></person-group><article-title>A multicenter, randomized, controlled clinical trial of
transfusion requirements in critical care. Transfusion Requirements in
Critical Care Investigators, Canadian Critical Care Trials
Group</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><issue>6</issue><fpage>409</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">9971864</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferraris</surname><given-names>VA</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Despotis</surname><given-names>GJ</given-names></name><name><surname>Hammon</surname><given-names>JW</given-names></name><name><surname>Reece</surname><given-names>TB</given-names></name><name><surname>Saha</surname><given-names>SP</given-names></name><etal/></person-group><article-title>2011 update to the Society of Thoracic Surgeons and the Society
of Cardiovascular Anesthesiologists blood conservation clinical practice
guidelines</article-title><source>Ann Thorac Surg</source><year>2011</year><volume>91</volume><issue>3</issue><fpage>944</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">21353044</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stover</surname><given-names>EP</given-names></name><name><surname>Siegel</surname><given-names>LC</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>J</given-names></name><name><surname>Body</surname><given-names>SC</given-names></name><name><surname>Maddi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Variability in transfusion practice for coronary artery bypass
surgery persists despite national consensus guidelines: a 24-institution
study. Institutions of the Multicenter Study of Perioperative Ischemia
Research Group</article-title><source>Anesthesiology</source><year>1998</year><volume>88</volume><issue>2</issue><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">9477051</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodnough</surname><given-names>LT</given-names></name><name><surname>Johnston</surname><given-names>MF</given-names></name><name><surname>Toy</surname><given-names>PT</given-names></name></person-group><article-title>The variability of transfusion practice in coronary artery bypass
surgery. Transfusion Medicine Academic Award Group</article-title><source>JAMA</source><year>1991</year><volume>265</volume><issue>1</issue><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">1984129</pub-id></element-citation></ref></ref-list></back></article>